Effects of anti-somatostatin agents on glucose metabolism.
Diabetes Metab
; 43(5): 411-415, 2017 Oct.
Article
in En
| MEDLINE
| ID: mdl-28579289
ABSTRACT
The anti-somatostatin agents used to treat acromegaly, Cushing's disease and neuroendocrine tumours also have hyperglycaemic effects. This is particularly true for pasireotide. Hyperglycaemic events are seen in 57-73% of patients with Cushing's treated with pasireotide, with a need to initiate antidiabetic treatment in about 50% of these patients. In acromegaly, treatment with pasireotide induces hyperglycaemia in 29-61% of patients. Pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of GLP-1 and GIP, and potentially also due to a direct inhibitory effect of pasireotide on beta cells. Close monitoring of blood glucose is mandatory in all patients during the first 3 months of treatment with pasireotide. Where necessary, antidiabetic treatment should be initiated, preferably with a DPP-4 inhibitor or a GLP-1 receptor agonist, both of which have proven efficacy in the control of hyperglycaemia induced by pasireotide.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Somatostatin
/
Carbohydrate Metabolism
/
Glucose
/
Hyperglycemia
Limits:
Humans
Language:
En
Journal:
Diabetes Metab
Year:
2017
Document type:
Article